What If Your Chemo Came in a Pill Instead of a Needle?

Paclitaxel is one of the most widely used chemotherapy drugs on the planet. It's been shrinking tumors since the early '90s. It's derived from the bark of the Pacific yew tree, which means nature basically invented cancer treatment and then made it almost impossible to swallow - literally. The drug doesn't dissolve in water, so for decades, the only way to get it into your body has been through an IV drip, mixed with a solvent called Cremophor EL that brings its own bag of problems: allergic reactions, hours tethered to a chair in an infusion center, and a side effect that patients dread almost as much as the cancer itself - peripheral neuropathy.

That tingling, burning, numb feeling in your hands and feet? Up to 97% of patients on taxane chemotherapy experience some version of it. And here's the kicker: for many, it doesn't go away when treatment stops. Studies show that 81% of patients still report neuropathy symptoms up to two years after their last infusion. Your cancer might be gone, but you still can't button your shirt.

So when a team of researchers announced that they'd figured out how to put paclitaxel in a pill - and that it actually works - well, that's the kind of plot twist oncology has been waiting for.

The Pill That Could

The drug is called DHP107 (brand name Liporaxel), and it uses a lipid-based formulation to sneak paclitaxel past your stomach acid and into your bloodstream. No IV line. No Cremophor. No three-hour infusion session where you stare at ceiling tiles and wonder what your coworkers are doing.

The OPTIMAL trial, a multinational phase III study led by Dr. Sung-Bae Kim and published in Annals of Oncology, put this oral version head-to-head against standard IV paclitaxel in 549 patients with HER2-negative recurrent or metastatic breast cancer [1]. The question was simple: can a pill do what the needle does?

Spoiler: Yes, It Can

Patients taking oral DHP107 had a median progression-free survival of 10.0 months, compared to 8.5 months for the IV group (HR 0.869, 95% CI 0.707-1.068). That's not just non-inferior - it's a numerical advantage. Overall survival was virtually identical at around 32-33 months in both arms. The oral group even had higher objective response rates (45.8% vs. 39.7%) and disease control rates (93.5% vs. 86.4%) [1].

Translation for non-statisticians: the pill worked at least as well as the IV, and in some measures, it worked better.

The Neuropathy Win

Here's where it gets really interesting. Peripheral neuropathy - that hand-and-foot nightmare - dropped from 48.3% in the IV group to 37.9% with oral DHP107 [1]. Hypersensitivity reactions fell too. And there were zero treatment-related deaths in the oral arm.

Why the difference? The leading theory involves ditching Cremophor EL. That oily solvent isn't just a passive delivery vehicle. Preclinical research has shown it causes axonal swelling, degeneration, and demyelination all on its own [2]. Remove the solvent, reduce the nerve damage. Elegant, really.

The Trade-Off (Because There's Always One)

Before you start campaigning for chemo pills in vending machines, there are caveats. DHP107 came with higher rates of neutropenia (81.6% vs. 59.3%), more febrile neutropenia (6.1% vs. 0.8%), and increased GI side effects like nausea, diarrhea, and vomiting [1]. Your immune system takes a slightly bigger hit, and your stomach knows about it.

But these are generally manageable toxicities, and for many patients, the calculus is straightforward: nausea you can treat with anti-emetics vs. nerve damage that might never fully resolve. That's not a hard choice.

Why This Actually Matters

Here's the thing about cancer treatment that doesn't get enough airtime: logistics are brutal. Weekly IV paclitaxel means weekly trips to the infusion center. For patients in rural areas, that's hours of travel. Studies consistently show that roughly 77% of cancer patients prefer oral chemotherapy when given the choice, citing less disruption to daily life and fewer problems with IV access [3].

An oral option means fewer hospital visits, less time away from work and family, lower transportation costs, and - not insignificantly - the psychological relief of not being hooked up to an IV. Treatment that patients can tolerate and actually adhere to tends to produce better outcomes. That's not rocket science; it's just human nature.

The OPTIMAL trial doesn't just add another option to the oncologist's toolkit. It challenges a 30-year assumption that paclitaxel has to come through a needle. For the roughly 2 million people diagnosed with breast cancer worldwide each year, that's a pretty big deal.

References

1. Xu B, Kim S-B, Seo JH, et al. OPTIMAL: A multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer. Ann Oncol. 2026. DOI: 10.1016/j.annonc.2026.03.002. PMID: 41833903

2. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-1598. DOI: 10.1016/S0959-8049(01)00171-X

3. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist. 2001;6(Suppl 4):12-16. DOI: 10.1634/theoncologist.6-suppl_4-12

4. Kim S-B, Seo JH, Ahn J-H, et al. Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Ther Adv Med Oncol. 2021;13:17588359211061989. DOI: 10.1177/17588359211061989. PMCID: PMC8679020

5. Ezendam NPM, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510-517. DOI: 10.1016/j.ygyno.2014.09.016

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.